Drugs / Recombinant human plasma gelsolin
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT03466073 | Aug 2018 → Apr 2019 | pneumonia | BioAegis Therapeutics Inc. | Completed | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| Phase 2 | NCT06216366 Comparator | Aug → Oct 2025 overdue | decompression sickness | BioAegis Therapeutics Inc. | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04358406 Comparator | Jul 2020 → May 2021 | COVID-19 | BioAegis Therapeutics Inc. | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Recombinant Human Plasma Gelsolin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03466073 ↗ |
| Known as | Rhu-pGSN | “Recombinant human plasma gelsolin (Rhu-pGSN)” NCT04358406 ↗ |
| Modality | Protein / enzyme biologic | “Recombinant human plasma gelsolin lyophilized for reconstitution, reconstituted in sterile water” NCT03466073 ↗ |
| Route | Intravenous | “Intravenous administration of recombinant human plasma gelsolin at 6 mg/kg” NCT03466073 ↗ |